经皮卵圆孔未闭封堵术用于卒中二级预防:网状Meta分析
该系统综述与网状Meta分析纳入6项随机对照试验,评估卵圆孔未闭封堵术对比药物治疗的安全性与有效性。封堵术与复发性缺血性卒中风险降低(RR 0.42,95%CI 0.20-0.91)及缺血性卒中/TIA风险降低(RR 0.65,95%CI 0.48-0.88)相关,但新发心房颤动风险增加(RR 4.59,95%CI 2.01-10.45)。
要点
- 封堵术较药物治疗降低复发性缺血性卒中风险(RR 0.42,95%CI 0.20-0.91)。
- 封堵术较药物治疗降低缺血性卒中/TIA风险(RR 0.65,95%CI 0.48-0.88)。
- 封堵术较药物治疗增加新发心房颤动风险(RR 4.59,95%CI 2.01-10.45)。
核心结论
- 卵圆孔未闭封堵术与复发性缺血性卒中或缺血性卒中/TIA风险降低相关,与新发心房颤动风险增加相关。
研究设计与样本
- 系统综述与网状Meta分析,纳入6项随机对照试验,比较封堵术与药物治疗及不同封堵装置。
主要发现
- 封堵术较药物治疗降低复发性缺血性卒中风险(RR 0.42,95%CI 0.20-0.91)。
- 封堵术较药物治疗降低缺血性卒中/TIA风险(RR 0.65,95%CI 0.48-0.88)。
- 封堵术较药物治疗增加新发心房颤动风险(RR 4.59,95%CI 2.01-10.45)。
- 间接分析中,Amplatzer装置较STARFlex装置降低新发心房颤动风险(RR 0.25,95%CI 0.10-0.65)。
- 间接分析中,GORE装置较STARFlex装置降低新发心房颤动风险(RR 0.28,95%CI 0.08-0.95)。
关键数值与推荐
- 复发性缺血性卒中:封堵术 vs 药物治疗 RR 0.42(95%CI 0.20-0.91)。
- 缺血性卒中/TIA:封堵术 vs 药物治疗 RR 0.65(95%CI 0.48-0.88)。
- 新发心房颤动:封堵术 vs 药物治疗 RR 4.59(95%CI 2.01-10.45)。
- 新发心房颤动:Amplatzer vs STARFlex RR 0.25(95%CI 0.10-0.65)。
- 新发心房颤动:GORE vs STARFlex RR 0.28(95%CI 0.08-0.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines report no benefit for patent foramen ovale (PFO) closure compared to medical treatment in patients with cryptogenic ischemic stroke (IS) or TIA. Two recent randomized controlled clinical trials have challenged these recommendations. METHODS: We performed a systematic review and network meta-analysis of randomized controlled trials to estimate the safety and efficacy of closure compared to medical treatment, and to compare available devices. We conducted pairwise meta-analyses for closure vs medical therapy, irrespective of the device used, and for each device vs medical therapy. RESULTS: Our literature search highlighted 6 studies. PFO occlusion was associated with reduced risk of recurrent IS (risk ratio [RR] 0.42, 95% confidence interval [CI] 0.20-0.91) and IS/TIA (RR 0.65, 95% CI 0.48-0.88) but with increased risk of new-onset atrial fibrillation (AF) (RR 4.59, 95% CI 2.01-10.45) compared to medical treatment. In indirect analyses, both Amplatzer (AMP) and GORE devices were found to be associated with a lower risk of new-onset AF compared to STARFlex (SFX) (RR 0.25, 95% CI 0.10-0.65 and RR 0.28, 95% CI 0.08-0.95). Moreover, AMP was found to be associated with a lower risk of recurrent IS/TIA events compared to the SFX device (RR 0.35, 95% CI 0.14-0.91). In the clustered ranking plot on the risk of IS against new-onset AF, GORE was comparable to AMP; however, on the risk of IS/TIA against new-onset AF, AMP appeared to be superior to the GORE device. In both ranking plots, SFX was highlighted as the worst option. CONCLUSION: PFO closure is associated with reduced risk of recurrent IS or IS/TIA and with increased risk of new-onset AF.
引用
- Tsivgoulis G, Katsanos AH, Mavridis D, et al. Percutaneous patent foramen ovale closure for secondary stroke prevention: Network meta-analysis. Neurology. 2018. PMID: 29875217. doi:10.1212/WNL.0000000000005739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。